Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761868 | 0.94 | GSK3B (0.52) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5388606 | 0.85 | GSK3B (0.54) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5875477 | 0.84 | MAPK14 (0.53) | GSK3BMAPK14MERTKMAPK10 | |
| SCHEMBL5457524 | 0.84 | GSK3B (0.46) | GSK3BMAPK14MERTKMAPK10 | |
| SCHEMBL5388940 | 0.83 | MAPK14 (0.53) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5395995 | 0.83 | GSK3B (0.59) | GSK3BMAPK14EGFRRAF1ADORA3 | |
| SCHEMBL5388005 | 0.83 | MAPK14 (0.53) | GSK3BMAPK14MERTKMAPK10 | |
| SCHEMBL5452937 | 0.83 | MAPK14 (0.52) | GSK3BMAPK14MERTKMAPK10 | |
| SCHEMBL5452168 | 0.82 | GSK3B (0.45) | GSK3BMAPK14MERTKMAPK10 | |
| SCHEMBL5460142 | 0.82 | GSK3B (0.45) | GSK3BMAPK14MERTKMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7034030-B2 | Pyralopyridines, process for their preparation and use as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | ALBERTI MICHAEL J | 2006-03-16 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058319-A1 | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | CYP3A5, CYP3A4, CYP3A7 | GSK3B 2419/4885MAPK14 2256/4885EGFR 3870/4885 |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | GSK3B 326/4885MAPK14 77/4885EGFR 786/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | GSK3B 3047/4885MAPK14 1551/4885EGFR 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.